These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 19959491

  • 21. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
    Alioğlu B, Kılıç N, Şimşek E, Dallar Y.
    J Clin Res Pediatr Endocrinol; 2012 Sep; 4(3):146-50. PubMed ID: 22985614
    [Abstract] [Full Text] [Related]

  • 22. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH, Rijken DC.
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [Abstract] [Full Text] [Related]

  • 23. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases.
    Saibeni S, Bottasso B, Spina L, Bajetta M, Danese S, Gasbarrini A, de Franchis R, Vecchi M.
    Am J Gastroenterol; 2004 Oct; 99(10):1966-70. PubMed ID: 15447757
    [Abstract] [Full Text] [Related]

  • 24. Assessment of the role of thrombin activatable fibrinolysis inhibitor in retinal vein occlusion.
    Gumus K, Kadayifcilar S, Eldem B, Ozcebe O.
    Retina; 2007 Jun; 27(5):578-83. PubMed ID: 17558319
    [Abstract] [Full Text] [Related]

  • 25. TAFI and PAI-1 levels in human sepsis.
    Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA.
    Thromb Res; 2006 Jun; 118(2):205-12. PubMed ID: 16009400
    [Abstract] [Full Text] [Related]

  • 26. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
    Xu CW, Wang LL, Wu XB, Zhao JJ, Du YM, Jiang CY.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146
    [Abstract] [Full Text] [Related]

  • 27. Thrombin activatable fibrinolysis inhibitor (TAFI) in stable angina pectoris patients undergoing coronary artery bypass grafting (CABG).
    Lisowski P, Małyszko J, Hirnle T, Lisowska A, Jackowski R, Małyszko JS, Buzun L, Myśliwiec M.
    Rocz Akad Med Bialymst; 2005 Aug; 50():166-72. PubMed ID: 16358959
    [Abstract] [Full Text] [Related]

  • 28. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
    Ricart JM, Ramón LA, Vayá A, España F, Santaolaria ML, Todolí J, Castelló R, Fontcuberta J, Estellés A.
    Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
    [Abstract] [Full Text] [Related]

  • 29. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients.
    Rigla M, Wägner AM, Borrell M, Mateo J, Foncuberta J, de Leiva A, Ordóñez-Llanos J, Pérez A.
    Metabolism; 2006 Nov; 55(11):1437-42. PubMed ID: 17046544
    [Abstract] [Full Text] [Related]

  • 30. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC, Middeldorp S, Tekelenburg W, van den Ende AE, Tans G, Prins MH, Rosing J, Büller HR, Bouma BN.
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [Abstract] [Full Text] [Related]

  • 31. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
    Chengwei X, Xiaoli M, Yuan Z, Li P, Shengjiang W, Chao Y, Yunshan W.
    Blood Coagul Fibrinolysis; 2013 Oct; 24(7):698-703. PubMed ID: 23624357
    [Abstract] [Full Text] [Related]

  • 32. Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
    Shantsila E, Montoro-García S, Tapp LD, Apostolakis S, Wrigley BJ, Lip GY.
    Thromb Haemost; 2012 Jul; 108(1):32-40. PubMed ID: 22538774
    [Abstract] [Full Text] [Related]

  • 33. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 34. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S.
    Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
    [Abstract] [Full Text] [Related]

  • 35. Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors.
    Agirbasli M, Cincin A, Baykan OA.
    J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):22-6. PubMed ID: 18404606
    [Abstract] [Full Text] [Related]

  • 36. Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules.
    Akinci B, Demir T, Comlekci A, Yener S, Ozcan MA, Karaoglu O, Yuksel F, Secil M, Yesil S.
    Med Princ Pract; 2011 Mar; 20(1):23-8. PubMed ID: 21160209
    [Abstract] [Full Text] [Related]

  • 37. Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy.
    Akinci B, Demir T, Saygili S, Yener S, Alacacioglu I, Saygili F, Bayraktar F, Yesil S.
    Diabetes Res Clin Pract; 2008 Jul; 81(1):93-6. PubMed ID: 18406001
    [Abstract] [Full Text] [Related]

  • 38. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
    Oral B, Mermi B, Dilek M, Alanoğlu G, Sütçü R.
    Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106
    [Abstract] [Full Text] [Related]

  • 39. A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma.
    Neill EK, Stewart RJ, Schneider MM, Nesheim ME.
    Anal Biochem; 2004 Jul 15; 330(2):332-41. PubMed ID: 15203340
    [Abstract] [Full Text] [Related]

  • 40. An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma.
    Kim PY, Foley J, Hsu G, Kim PY, Nesheim ME.
    Anal Biochem; 2008 Jan 01; 372(1):32-40. PubMed ID: 17967438
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.